aqueous-shunt
(2)
Rui Jing
Rui Jing Jiang is the Founder and CEO of Avisi Technologies, a Redwood City-based clinical-stage medical device company developing VisiPlate, the world's thinnest freestanding ophthalmic implant for treating glaucoma. Built on University of Pennsylvania nanotechnology, VisiPlate is a multichannel aqueous shunt composed of alumina and Parylene-C that is 20 times thinner than a human hair. Rui Jing co-founded the company in 2017 as a junior at Penn's Wharton School, won the $100,000 President's Innovation Prize in 2018, secured FDA Investigational Device Exemption approval in October 2025 for the US SAPPHIRE trial, and closed a $10.7M Series A in February 2026 to advance pivotal clinical development.
Robert Chang
Robert Chang is the President and CEO of Myra Vision, a Campbell, California medtech company developing the Calibreye Titratable Glaucoma Therapy (TGT) Surgical System - an adjustable aqueous shunt designed to give glaucoma surgeons real-time, non-invasive control over intraocular pressure. With over 30 years of medical device executive experience spanning co-founding Ample Medical, leading MVRx, and serving as CTO at Sadra Medical (acquired by Boston Scientific), Chang brings a rare combination of hands-on engineering depth and serial CEO-level leadership to one of ophthalmology's most intractable surgical challenges. Myra Vision has raised $50M+ across seed, Series A, and a $25M Series B in 2023, and in early 2026 enrolled its first patient in the FDA-approved ADAPT pivotal study.